HOUSTON, Sept. 25 /PRNewswire/ -- SeqWright, Inc., an international leader in the field of contract genomic services, announced today an agreement with Applied Biosystems (ABI) to purchase ABI's next generation SOLiD(TM) genetic analysis system, a development which will enable SeqWright to offer commercial access to the latest in Sequencing Technology. The agreement reflects a long standing relationship between SeqWright and ABI that grows stronger with time.
The SOLiD(TM) platform will dramatically enhance SeqWright's ability to offer cutting-edge services in areas including whole genome sequencing, re-sequencing, Transciptome analysis, small RNA discovery, SNP detection, Epigenomic and Metagenomic studies.
In addition, the SOLiD(TM) platform significantly increases the sequencing capacity at SeqWright and provides its customers with access to the Next Generation sequencing platform with the highest throughput and accuracy currently available.
The adoption of ABI's Next Generation platform is part of SeqWright's ongoing commitment to remain the industry leader in DNA sequencing and contract genomic services providing access to the latest in technology and bioinformatics support.
"This continues SeqWright's tradition of providing its customers early access to the latest in commercially relevant technology. In providing this new service, we will be opening doors to research limited only by the imaginations of the talented scientists around the world with whom we will be working over the coming years," said David Buck, Ph.D., Vice President of Operations.
SeqWright Incorporated is a world-class genomic services support organization with more than a decade of experience specializing in providing access to state of the art Molecular Biology applications including DNA sequencing, customized cloning, QPCR and Microarray services in a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit http://www.seqwright.com.
|SOURCE SeqWright, Inc.|
Copyright©2007 PR Newswire.
All rights reserved